Harmony Biosciences Holdings, Inc. (HRMY) Stock

Harmony Biosciences Holdings, Inc. (HRMY) is a Healthcare stock trading at $33.30 (as of 2026-06-18), with a market capitalization of $1.83B and a trailing P/E of 12.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company that develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX, is used to treat excessive daytime sleepiness in adult patients with narcolepsy.

Valuation — source: SEC EDGAR (first-party)
Price$33.30
Market Cap$1.83B
P/E Ratio12.7
EV / EBITDA7.4
Price / Book2.01
Price / Sales2.03
DCF Value (model)$161.95
DCF Upside vs Price386.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$868.45M
Net Margin18.3%
Return on Equity16.0%
Debt / Equity0.17
Current Ratio3.58
Revenue Growth (YoY)16.6%
EPS Growth (YoY)-29.1%
Financial Health — source: SEC EDGAR
Altman Z-Score4.90 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E12.7
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-39.2%
vs Industry-26.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($198.03M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJeffrey Dayno
Employees268
CountryUS
IPO Date2020-08-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Immunome, Inc. (IMNM)
  • Sarepta Therapeutics, Inc. (SRPT)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Recursion Pharmaceuticals, Inc. (RXRX)
  • Aurinia Pharmaceuticals Inc. (AUPH)
  • Maze Therapeutics, Inc. (MAZE)
  • Olema Pharmaceuticals, Inc. (OLMA)
  • ImmunityBio, Inc. (IBRX)
HRMY earnings history · HRMY institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.